Recent advances in the targeting of FLT3 in AML
MRD as a marker for depth of remission in CLL
CAR T-cell development in Europe – where are we in CLL?
Promising results for MM treatment with natural killer cells
Promising results for venetoclax combination therapies in elderly AML